In addition, study of the genetic variation in IL-4/IL-4R, IL-5, IL-9, IL-13 cytokines, high affinity FcεRI IgE receptor as well as HLA genes and also the evaluation of the level of the cytokines at different time points post-chemotherapy could assist in delineating specifically the underlying mechanism responsible for atopic manifestation post-chemotherapy in some ALL patients. This evidence concerns the gene IL4 and acute lymphoblastic leukemia.